Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety roll-over study of osilodrostat in endogenous Cushing's syndrome
2017-002840-34Phase 2Completed
- Sponsor
- Recordati SpA
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osilodrostat in Cushing's syndrome, sponsored by Recordati SpA. Primary endpoint: Frequency and severity of AEs/SAEs. Started May 2018; status: completed.
02
Drugs
osilodrostat
03
Conditions
Cushing's syndrome
Beyond the preview
Go deeper on 2017-002840-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002840-34.